According to this theory, the inhibition of PARP is a potential therapeutic strategy for the treatment of types of cancer that have specific DNA repair defects, including those that arise in individuals who are carriers of mutations in BRCA1 or BRCA2 (23). This evidence concerns the gene BRCA2 and cancer.